According to Teva Pharmaceutical Industries Ltd. its second-quarter profit rose by 25 percent due to sales of the multiple sclerosis drug Copaxone [glatiramer acetate] and savings from its acquisition of Barr Pharmaceuticals Inc. The Barr deal gave Teva access to around 25 percent of the market for generics in the US where the sale of its new generic version of the hyperactivity drug Adderall XR [amphetamine and dextroamphetamine] was partly responsible for the 36 percent rise in revenue.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지